Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 61-71

  Viljoen, Adie ^a   Wierzbicki, Anthony S ^b  

^a LISTER HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Laropiprant; Lipid abnormalities; Niacin

Indexed keywords

ANTIOXIDANT; CHOLESTEROL; CLOFIBRATE; COLESTIPOL; DIACYLGLYCEROL ACYLTRANSFERASE 2; ESTROGEN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MK 0542; NICOTINIC ACID; PLACEBO; SIMVASTATIN; THYROXINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME INHIBITION; FLUSHING; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID DEGRADATION; LIPOLYSIS; LIVER DISEASE; MEDICAL DECISION MAKING; MYOPATHY; NONHUMAN; PATIENT DECISION MAKING; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; REVIEW; RISK REDUCTION; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME;

EID: 77955480126     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s7302     Document Type: Review

References (102)

1. World Health Organization. The top 10 causes of death. [Fact sheet No310]; 2007 [cited Jan 2010]. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/index.html
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.
3. Lusis AJ. Atherosclerosis. Nature. 2000 Sep 14;407:233-241.
4. Viljoen A. New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease. Recent Pat Cardiovasc Drug Discov. 2008;3:84-91.
5. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.
6. British Cardiac Society, British Hypertension Society, Diabetes UK; HEART UK, Primary Care Cardiovascular Society, Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91 Suppl 5: v1-v52.
7. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
8. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol- lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125.
9. Kidd J. Life after statin patent expiries. Nat Rev Drug Discov. 2006;10:813-814.
10. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):III39-III43.
11. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
12. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225-1228.
13. Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28:26-35.
14. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B-69B.
15. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-160.
16. Caslake MJ, Packard CJ. Phenotypes, genotypes and response to statin therapy. Curr Opin Lipidol. 2004;15:387-392.
17. Maitland-van der Zee AH, Boerwinkle E. Pharmacogenetics of response to statins: where do we stand? Curr Atheroscler Rep. 2005;7: 204-208.
18. Viljoen A, Wierzbicki AS. Enhanced LDL-C reduction: lower is better. Does it matter how? Int J Clin Pract. 2008;62:518-520.
19. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005;46:1855-1862.
20. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2007;28:2375-2414.
21. Garber AM. An uncertain future for cardiovascular drug development? N Engl J Med. 2009;360:1169-1171.
22. Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. J Pharmacol Exp Ther. 2008;324:883-893.
23. Berg JM, Tymoczko JL, Stryer L, editors. Biochemistry, 5th ed. New York: W.H. Freeman and Company, 2002.
24. Viljoen A. Resurrecting an old drug - a flash in the pan or here to stay? Int J Clin Pract. 2009;63:3-6.
25. Hegyi J, Schwartz R, Hegyi V. Pellagra: dermatitis, dementia, and diar-rhoea. Int J Dermatol. 2004;43:1-5.
26. Koehn CJ, Elvehjem CA. Further studies on the concentration of the antipellagra factor. J Bio Chem. 1937;118:693-699.
27. Altschul R, Herman IH. Influence of oxygen inhalation on cholesterol metabolism. Arch Biochem Biophys. 1954;51:308-309.
28. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem. 1955;54:558-559.
29. Parsons WB, Achor RW, Berge KG, McKenzie BF, Barker NW. Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations. Proc Staff Meet Mayo Clin. 1956;31:377-390.
30. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
31. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
32. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
33. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223: 405-418.
34. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110: 3512-3517.
35. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
36. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima - media thickness. N Engl J Med. 2009;361:2113-2122.
37. Wierzbicki AS. Surrogate markers, atherosclerosis and cardiovascular disease prevention. Int J Clin Pract. 2008;62:981-987.
38. Blumenthal RS, Michos ED. The HALTS trial - halting atherosclerosis or halted too early? N Engl J Med. 2009;361:2178-2180.
39. National Heart Lung and Blood Institute. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. ClinicalTrials.gov. [Online]. 2008 October 15. [cited January 2010] Available from URL: http://clinicaltrials.gov/ct2/show/NCT00461630
40. National Heart Lung and Blood Institute. Niacin plus statin to prevent vascular events: AIM-HIGH. ClinicalTrials.gov. [Online]. 2008 September 30. [cited October 30 2008] Available from URL: http:// www.clinicaltrials.gov/ct/show/NCT00120289
41. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258:94-114.
42. Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (nia- cin), the broad-spectrum lipid drug. Int J Clin Pract. 2004;58:706-713.
43. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: From ultracentrifugation to homogeneous assays. Clin Chem. 2001;47:1579-1596.
44. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746-756.
45. Karlsson H, Leanderson P, Tagesson C, et al. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two dimensional gel electrophoresis and mass spectrometry. Proteomics. 2005;5:551-565.
46. Van JT, Pan J, Wasty T, et al. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol. 2002;89:1306-1308.
47. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoproteinsubfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553-559.
48. Rizzo M, Berneis K. Low-density lipoprotein size and cardio- vascular risk assessment. QJM. 2006;99:1-14.Erratum in: QJM. 2007;100:147.
49. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006;113:1556-1563.
50. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis. 1988;8: 207-211.
51. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86:19L-22L.
52. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 2006;113:2548-2455.
53. Barter P. Effects of inflammation on high-density lipoproteins. Arte- rioscler Thromb Vasc Biol. 2002;22:1062-1063.
54. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syn- dromes: a randomized controlled trial. JAMA. 2003;290:2292-3000.
55. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357: 2109-2122.
56. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem. 2008;54:788-800.
57. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation. 1991;84:129-139.
58. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men: prospective results from the Quebec Cardio- vascular Study. Arterioscler Thromb Vasc Biol. 1997;17:1098-1105.
59. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
60. Yu S, Yarnell JW, Sweetnam P, Bolton CH. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis. 2003;166:331-338.
61. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47:1097-1104.
62. Viljoen A, Wierzbicki AS. Potential options to treat hypertriglyceridaemia. Curr Drug Targets. 2009;10:356-362.
63. McBride PE. Triglycerides and risk for coronary heart disease. JAMA. 2007;298:336-338.
64. Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab. 2007;92:1581-1589.
65. Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mor- tality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation. 2000;101:2777-2782.
66. Brunzell JD. Clinical practice. Hypertriglyceridemia. N Engl J Med. 2007;357:1009-1017.
67. Mao EQ, Tang YQ, Zhang SD. Formalized therapeutic guideline for hyperlipidemic severe acute pancreatitis. World J Gastroenterol. 2003;9:2622-2626.
68. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353: 46-57.
69. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heartdisease: meta-analysis of prospective studies. Circulation. 2000;102: 1082-1085.
70. Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331-2339.
71. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518-2528.
72. Kathiresan S. Lp(a) Lipoprotein redux - from curious molecule to causal risk factor. N Engl J Med. 2009;361:2573-2574.
73. Martin SC, Viljoen A. The value of a specialist lipid clinic. Int J Clin Pract. 2008;62:961-966.
74. Kamanna VS, Ganji SH, Kashyap ML. Niacin: an old drug rejuvenated. Curr Atheroscler Rep. 2009;11:45-51.
75. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy and safety. Curr Opin Lipidol. 2007;18:415-420.
76. Carlson LA, Hanngren A. Initial distribution in mice of 3H-labelled nicotinic acid studied by autoradiography. Life Sci. 1964;3:867-871.
77. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003;278: 9869-9874.
78. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101:20B-26B.
79. Kamal-Bahl S, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol. 2007;99:530-534.
80. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47:1097-1104.
81. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998;82:74U-81U.
82. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89:672-678.
83. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007;192:432-437.
84. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract. 2009:1369-1377.
85. Grundy SM, Vega GL, McGovern ME, et al; Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162:1568-1576.
86. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2005;95:254-257.
87. American Diabetes Association. Standards of medical care indiabetes - 2008. Diabetes Care. 2008;31:S12-S54.
88. American Diabetes Association. Management of dyslipidemia in adultswith diabetes. Diabetes Care.1998;21:179-182.
89. National Institute for Health and Clinical Excellence. Diabetes - type2 (update). [Online]. 2008 May [cited January 2010]; Available from URL: http://www.nice.org.uk/Guidance/CG66
90. Pike NB. Flushing out the role of GPR109A (HM74A) in the clinicalefficacy of nicotinic acid. J Clin Invest. 2005;115:3400-3.
91. Thakkar RB, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJ. Acetylsalicylic acid reduces niacin extended-release-inducedflushing in patients with dyslipidemia. Am J Cardiovasc Drugs.2009;9:69-79.
92. Auliffe M, Piechuta H, Nicoll-Griffith DA, et al. Discovery of apotent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydro cyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem. 2007;50:794-806.
93. Van Hecken A, Depré M, De Lepeleire I, et al. The effect ofMK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandinD (2)-induced nasal airway obstruction in healthy volunteers. Eur JClin Pharmacol. 2007;63:135-141.
94. Bindhu K, Maria M, Scott B, et al. Absorption, metabolism, andexcretion of [14C]MK-0524, a prostaglandin D2 receptor antagonist, in humans. Drug Metab Dispos. 2007;35:1196.
95. Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptorantagonist. Clin Pharmacol Ther. 2008;83:840-847.
96. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacyand tolerability of extended-release niacin/laropiprant in patients withprimary hypercholesterolaemia or mixed dyslipidaemia. Int J ClinPract. 2008;62:1959-1970.
97. Gleim G, Ballantyne CM, Liu N, et al. Efficacy and safetyprofile of co-administered ER niacin/laropiprant and simvastatin indyslipidaemia. Br J Cardiol. 2009;16:90-97.
98. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile ofextended-release niacin/laropiprant versus gradually titrated niacinextended-release in patients with dyslipidemia with and withoutischemic cardiovascular disease. Am J Cardiol. 2009;104:74-81.
99. Kush D, Hu DY, Ye P, et al. Flushing profile of extended-releaseniacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology. 2009;114:192-198.
100. Hughes S. Experts speculate on Cordaptive rejection. [Online]. 2008April 30 [cited January 2010]; Available from URL: http://www.theheart.org/article/860399.do.
101. Deyo RA. Gaps, tensions, and conflicts in the FDA approvalprocess: implications for clinical practice. J Am Board Fam Pract.2004;17:142-149.
102. Rosen C. An Audience with. Clifford Rosen. Nat Rev Drug Discov.2008;7:382.